Fig. 4From: A strategy to protect off-the-shelf cell therapy products using virus-specific T-cells engineered to eliminate alloreactive T-cellsCMVSTs expressing iCHAR can reduce expansion of responder alloreactive T-cells. a Responder PBMCs were co-culture with stimulator CMVSTs and flow cytometry analysis was perform on Day 0 and Day 8. Representative dot plots of co-cultures showing cell counts assessed by counting beads. HLA-A2 staining distinguishes between responder and stimulator cells. b Calculated fold change of cell counts from Day 0 to Day 8 of gated responder T-cells (mean ± SEM, n = 3). c Calculated fold change from Day 0 to Day 8 of gated stimulator CMVSTs (mean ± SEM, n = 3). Significance was determined by paired two-tailed Student’s t-test. *p < 0.05 compared to NT CMVST condition. R responder, S stimulatorBack to article page